Curis, a biotech company developing the drug emavusertib for cancer treatment, will announce its first quarter 2026 financial and operating results on May 12, 2026. The company will hold a conference call and webcast to discuss these results. Emavusertib is being tested in clinical trials for lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia, with orphan drug designations from the FDA and European Commission. This update is important for investors tracking Curis's progress in cancer drug development and financial health.
Revolut will stop supporting Tether's USDT stablecoin by August 31, 2026, to comply with the EU's MiCA regulations, which require stablecoins to have EU approval. Users can no longer buy USDT after July 6 and deposits will be disabled after July 30. ...
OpenAI's Stargate UK AI project, initially hailed as a £30 billion investment, has stalled after the company never visited a key planned site and paused the project citing high UK electricity costs and regulatory uncertainty. UK officials dispute the...
XRP climbed about 3% to an intraday high of $1.11 on July 3, rebounding from $1.02 two days earlier. This gain follows a buy signal from the Supertrend indicator and nearly $7 million in fresh inflows into XRP ETFs after a brief withdrawal period. Ri...
Kraken, the first official crypto partner of the 2026 World Cup, is running the "Here We Go! Sweepstakes" contest from June 20 to July 20, 2026. Traders earn one entry per dollar traded on eligible spot and instant trades, with a chance to win 1 full...
Delivra Health Brands has introduced LivRelief Itch Cream, a new product aimed at relieving itching caused by conditions like psoriasis, eczema, bug bites, and skin rashes. The cream uses a patented delivery system to penetrate the skin and combines ...
